SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Interim Management Statement

25 Jul 2018 07:00

RNS Number : 6360V
Victrex PLC
25 July 2018
 
 

 

 

 

25 July 2018

Victrex plc: Interim Management Statement

 'On track for a strong FY18'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its Interim Management Statement for the third quarter (Q3) covering the period 1 April to 30 June 2018.

Victrex has performed well since the end of the first half and cash generation has remained strong. Core business momentum has continued, with the majority of our markets in growth. Q3 saw a slightly lower contribution from the large Consumer Electronics order and with no volumes expected from this order in the fourth quarter, we will see a tougher Q4 comparative versus last year.

 

Medical revenue was in line with the prior year. Despite the challenging US Spine market, we still anticipate delivering meaningful revenue this year for our differentiated and innovative PEEK-OPTIMATM HA Enhanced product.

 

Overall, Q3 Group sales volume was up 14% to 1,161 tonnes (Q3 2017: 1,022 tonnes), with Group revenue up 10% to £84.0m (Q3 2017: £76.3m). Year to date Group sales volume of 3,417 tonnes is 19% up on the prior year (2017 YTD: 2,881 tonnes), with year to date Group revenue of £250.6m up 21% (2017 YTD: £207.3m).

Mega-programme progress

Victrex continues to focus on delivering further milestones in its growth pipeline and mega-programmes.

 

Following a commitment to deploy Magma's flexible oil & gas composite pipe by Tullow in West Africa, additional opportunities are under discussion, both with Tullow and other operators, in FY19. In Aerospace, construction of our US manufacturing facility, to support our TxV Aero Composites joint venture, is nearing completion, with prototype orders already in place. In Medical, following the agreement with Straumann Dental to enhance market access for our Juvora Dental product, we are in discussions for further customer agreements.

 

Currency

Currency remains in line with guidance for FY18, with approximately 90% of the FY18 currency benefit already seen in the first half, and a much lower benefit in the second half year. Looking ahead to 2019, over 50% of our currency hedges are in place. Although Sterling has slightly weakened since the end of our first half year, our guidance for FY19 remains similar, with an approximately £8m - £10m headwind to profits based on current rates and hedging in place, and reflecting some emerging raw material inflation.

 

Outlook

With continued momentum in our core business and milestones in our mega-programmes, we remain well positioned to continue driving growth as part of our Polymer & Parts strategy.

 

Although growth comparatives will be tougher in Q4, and we will see currency becoming a headwind, Victrex remains comfortable with full year expectations. Overall, we are on track to deliver a strong performance for FY18 as a whole.

 

 

Analyst & investor conference call

A conference call for analysts & investors will be held today, Wednesday 25 July at 08.00 BST.

Dial in details: +44 3333 000804 PIN: 96849285#

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations & Communications +44 (0) 7809 595831

Richard Armitage, Group Finance Director +44 (0) 1253 897700

Jakob Sigurdsson, Chief Executive +44 (0) 1253 897700

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of automotive, aerospace, energy (including manufacturing & engineering), electronics and medical. Every day, millions of people use products and applications, which contain our materials - from smart phones, aeroplanes and cars to oil and gas operations and medical devices. With over 35 years' experience, we develop world leading solutions in PEEK and PAEK based polymers, semi-finished and finished parts which shape future performance for our customers and our markets, and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTEASXLADDPEFF
Date   Source Headline
29th May 202611:00 amRNSTotal Voting Rights
18th May 20268:50 amRNSDirectorate change
11th May 20267:00 amRNSHalf-year Financial Report
30th Apr 202610:46 amRNSTotal Voting Rights
29th Apr 20264:28 pmRNSHolding(s) in Company
31st Mar 20261:37 pmRNSTotal Voting Rights
24th Mar 20264:29 pmRNSHolding(s) in Company
24th Mar 20262:03 pmRNSHolding(s) in Company
20th Mar 20269:38 amRNSHolding(s) in Company
27th Feb 20262:40 pmRNSTotal Voting Rights
27th Feb 20261:02 pmRNSHolding(s) in Company
24th Feb 202611:41 amRNSHolding(s) in Company
17th Feb 20263:06 pmRNSDirector/PDMR Shareholding
12th Feb 20263:26 pmRNSDirector/PDMR Shareholding
12th Feb 20263:22 pmRNSDirector/PDMR Shareholding
10th Feb 20262:43 pmRNSDirector/PDMR Shareholding
10th Feb 20269:00 amRNSDirectorate change
6th Feb 20261:33 pmRNSResult of AGM
6th Feb 20267:00 amRNSQ1 Trading Update
30th Jan 202611:49 amRNSTotal Voting Rights
28th Jan 202612:25 pmRNSHolding(s) in Company
22nd Jan 202610:21 amRNSHolding(s) in Company
20th Jan 20261:26 pmRNSAdditional Listing
31st Dec 20259:00 amRNSTotal Voting Rights
31st Dec 20259:00 amRNSTotal Voting Rights
22nd Dec 202512:00 pmRNSAnnual Financial Report
22nd Dec 202512:00 pmRNSAnnual Financial Report
18th Dec 202511:49 amRNSDirector/PDMR Shareholding - Replacement
17th Dec 20253:42 pmRNSDirector/PDMR Shareholding
17th Dec 202512:08 pmRNSDirector/PDMR Shareholding
15th Dec 20259:00 amRNSDirector/PDMR Shareholding
11th Dec 20258:52 amRNSDirector/PDMR Shareholding
5th Dec 20259:30 amRNSShare purchase by incoming Director (incoming CEO)
4th Dec 20259:06 amRNSFinancial Calendar Update
2nd Dec 20257:00 amRNSPreliminary Results
1st Dec 202510:49 amRNSBlock listing Interim Review
28th Nov 20259:27 amRNSTotal Voting Rights
20th Nov 20259:05 amRNSAdditional Listing
7th Nov 202510:39 amRNSHolding(s) in Company
31st Oct 20258:58 amRNSTotal Voting Rights
21st Oct 20257:30 amRNSCEO Succession update
3rd Oct 202511:36 amRNSHolding(s) in Company
3rd Oct 20259:03 amRNSHolding(s) in Company
30th Sep 20259:54 amRNSTotal Voting Rights
29th Aug 202510:16 amRNSTotal Voting Rights
31st Jul 20259:14 amRNSTotal Voting Rights
9th Jul 20251:02 pmRNSHolding(s) in Company
8th Jul 20253:33 pmRNSDirector/PDMR Shareholding
8th Jul 20257:00 amRNSDirectorate change: CEO succession
8th Jul 20257:00 amRNSQ3 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.